Kodiak Sciences (KOD) logo

Kodiak Sciences (KOD) stock

Retinal medicines , market cap $6.4B

After-hours Fri
$97.26
+0.09%

Close $97.17 -0.75%

Quality Score
5
Below Average
In its industry
#50of 273
Checks firing
3of 14
Trending up
From 52-week high
-13.8%
under its best in a year

KOD's Quality Score fell 2 points on Fri, Nov 20, to 5. Its quiet day ended (2 chart checks stopped).

Follow KOD's trial news. Pro members can get an alert when Kodiak Sciences files news, and see its trials, share raises, and its CEO's filings.

Get an alert when KOD files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextDec 2026“Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026…”Trial data · SEC filing · Nov 12
Cash$88.7M, about 2 quarters at the last year's spendingOn Sep 30 · the company says “into 2027”

Why KOD beats the market

Up 3,899% over three years while the S&P 500 rose 58%.

  • Its Nov 12 results: net loss per share, basic and diluted narrowed to $1.05, from $1.16 a year before. It rose 3% on Nov 13.

Sources: Price history, Nov 20, 2026; Company release, Nov 12, 2026

1 more reason, free with an account →See every reason on KOD →1 more reason why KOD beats the market, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on KOD

Key facts on KOD
Holding it backA $247M loss wider than $217M a year earlier
Latest filing8-K, Nov 12 Reported its quarterly results

KOD in the news

Mon Nov 9Kodiak Sciences stock hits 52-week high at 104.26 USD By Investing.com uk.investing.com and 1 more · yesterday 9:58 AM ET KOD closed +7.9% that day.

1 more big story on KOD in the past 12 months, for Pro members.

What's next

Tue Dec 1: Evercore ISI 9th Annual HealthCONx…Investor conference · date confirmed.

Expected to report Tue Mar 30, after the close

After its last 4 reports it closed +3.1% on average, higher 3 of 4 times.

Cash$88.7M, about 2 quarters at the last year's spendingOn Sep 30 · the company says “into 2027”

KOD catalysts

Coming up

6 more coming up and 3 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for KOD, and how long its cash lasts

Next step the company has named

Dec 2026“Topline data for Pivotal Analysis 1 (PEAK) are expected in December 2026 and Pivotal Analysis 2 (PEAK+PINNACLE) in 2Q 2027.”Trial data · SEC filing · Nov 12

What it means: the first look at a trial’s main results, as the company reports them.

A trial underway
PINNACLEPhase 3 · Recruiting · 300 people · main data estimated Feb 2027 · NCT06996080

3 more trials, 5 more milestones and 18 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 2 quarters

$88.7M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into 2027” (8-K, Nov 12).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Director BAKER BROS. ADVISORS LP bought 247,090 shares on Nov 5. 6 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Victor Perlroth’s 13 filings and quotes.

Get an alert when KOD files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

Why KOD scores 5

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. KOD scores 5 today, against a median of 9 over its last 20 recorded sessions.

  • +3Chart checks 3 of 14 firing right now, one point each
  • −1Profit A loss of $247M over the last four quarters, more than the $217M lost a year earlier, from the SEC filingsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
  • Long-term trend adds
  • Run-up adds
  • Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
  • Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
  • Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
  • Persistence adds
  • Insider trades adds

No effect today: Size, Growth, and News.

What every line is worth, and the reason behind it, on KOD and every other stock.Get in free →See the top 3 →Start Pro

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when KOD's Quality Score turns up

A free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

How KOD ranks in Biotech

KOD is #50 of 273 by Quality Score.

How KOD ranks in Biotech
RankStockQuality Score
50Kodiak Sciences (KOD) logoKODKodiak Sciences5

Net income over four quarters: KOD -$247M, BEAM -$108M, TWST -$130M, KYMR -$349M.

More in Biotech

When does KOD report earnings, and what happens after?

Expected to report Tue Mar 30, after the close (in 129 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What KOD reported on Nov 12, 2026

The quarter

The figures are not read from the release yet.

“The increase in R&D expenses in the third quarter of 2026 was primarily driven by increased clinical activities related to our active PEAK/PINNACLE and ALTO studies and increased manufacturing activities to support our Phase 3 programs.”

The filing on EDGAR

Where the sales came from

KOD's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

  • “The remaining decrease in G&A expenses was primarily driven by a non-cash non-recurring gain recognized upon termination of one of our Palo Alto, California building leases, in exchange for which we received an option to lease a separate building on the same campus with certain lease incentives.”

From its results filing (SEC filing · Nov 12)

2 more sentences, for Pro members.

The numbers

Market value
$6.4B
today
Free cash flow
-$173M
last 12 months

1 more figure, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on KOD: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-6.1%+3.4%+2.7%
May 7Aug 13Nov 12
ReportedGapReaction5
days
Nov 12, 2026After close+0.0%+2.7%-9.6%
Aug 13, 2026After close-6.5%+3.4%-0.3%
May 7, 2026After close-3.7%-6.1%-11.4%

KOD closed higher after 3 of its last 4 reports.

All 4 reports, and KOD's Quality Score going into each

KOD has 3 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on KOD, and all 14 on every stock.Get in free →See the top 3 →Start Pro

KOD RSI on Nov 20: 52.0, above its 50-day and 200-day averages

Not scored

RSI 52.0, MACD below signal, above both averages. Not scored.

The deep dive on KOD

5 more findings on KOD, each with its source, for Pro members.

KOD share count over time

19% more shares than a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of KOD outstanding, as filed
Shares
outstanding
As
of
65.4MNov 9, 2026
62.8MAug 6, 2026
62.6MApr 30, 2026
61.8MMar 19, 2026
Offerings, shelves, and splits of KOD, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Oct 20, 2026
Raised $160M in a sale of shares, about 2% of its market valueDec 17, 2025

KOD insider trades

One insider bought $181M across 86 filings in the last 6 months. No open-⁠market sales on record. The newest:

BuyBaker Bros. Advisors LP$15M10% ownerat $98.51 on Nov 4, filed Nov 6

All 86 insider filings on KOD from the last six months, for Pro members.

All KOD insider trades

KOD's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

Which ETFs hold KOD?

In ETFs: KOD is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Kodiak Sciences

Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.

124 employeesPalo Alto, CAkodiak.com

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on KOD and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn KOD's score around: 7 things
  • 4 more filings explained, a plain line each
  • Real-⁠time prices, no delay
BreakawayNov 6Baker Bros. Advisors LP bought KOD$15M at $98.51, filed Nov 6

Alerts are optional.

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: KOD's Quality Score is 5 (Below Average), #50 of 273 in Biotech. Insiders bought $181M in the last 6 months (Form 4).

What does KOD's Quality Score say?

KOD scores 5 today, which Breakaway calls Below Average. It is #50 of 273 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 3,899% over three years while the S&P 500 rose 58%. Cash lasts about 2 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is KOD's Quality Score?

KOD scores 5 today, which Breakaway calls Below Average (0 to 5). That is #50 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind KOD's 5.

Are insiders buying KOD?

One insider bought $181M across 86 filings in the last 6 months. No open-⁠market sales on record. The newest is Baker Bros. Advisors LP, 10% owner, who bought $15M on Nov 4. Every filing, with the scored weight, for Pro members.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for Kodiak Sciences: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.